PrimeRFP SCOUT · Federal Contract Recompete Brief

75A50325F80013 — OSELTAMIVIR PHOSPHATE 75MG CAPSULES (NDC: 47781-470-13); 10 CT. BLISTERS PACKS AND OSELTAMIVIR PHOSPHATE 30MG CAPSULES…

OSELTAMIVIR PHOSPHATE 75MG CAPSULES (NDC: 47781-470-13); 10 CT. BLISTERS PACKS AND OSELTAMIVIR PHOSPHATE 30MG CAPSULES… is a federal award for Department of Health and Human Services (HHS) held by ALVOGEN. Estimated value $227.7M ($227.7M obligated). Current period of performance ends Jun 29, 2027. Last award drew 3 bidders.

$227.7M
Estimated Value
Jun 29, 2027
PoP End / Expires
3
Bidders (last award)
ALVOGEN
Incumbent

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See related expiring contracts →

Analysis

Public

ALVOGEN holds $284.8M across 11 federal awards, concentrated at Department of Health and Human Services (HHS). Competition previously drew 3 offers. Recompete timing centers on the Jun 29, 2027 PoP end — agencies typically plan 12–18 months ahead.

Contract facts

Federal
Contract number75A50325F80013
AgencyDepartment of Health and Human Services (HHS)
IncumbentALVOGEN
UEILJNNGDV77Y98
NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505
Parent IDIQ / IDVV797D70134
PoP end (current)Jun 29, 2027
Obligated$227.7M

OSELTAMIVIR PHOSPHATE 75MG CAPSULES (NDC: 47781-470-13); 10 CT. BLISTERS PACKS AND OSELTAMIVIR PHOSPHATE 30MG CAPSULES (NDC: 47781-468-13); 10 CT. BLISTERS PACKS.

Recompete timing

Public
Expiring in 316 days

Current PoP ends Jun 29, 2027 (316 days remaining). Agencies typically plan 12–18 months ahead — at 10.4 months out, that window is already open. The buying decision is likely already in motion.

Watch this contract — one email →

Incumbent footprint

Public record

ALVOGEN$284.8M obligated across 11 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)
Department of Health and Human Services (HHS)$284.8M · 100% of firm total
Open full company profile

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See the recompete window for 75A50325F80013
More in SCOUT
Track this contract →

Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open ALVOGEN’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract 75A50325F80013?

75A50325F80013 (OSELTAMIVIR PHOSPHATE 75MG CAPSULES (NDC: 47781-470-13); 10 CT. BLISTERS PACKS AND OSELTAMIVIR PHOSPHATE 30MG CAPSULES…) is a Department of Health and Human Services (HHS) award with an estimated value of $227.7M, currently held by ALVOGEN. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on 75A50325F80013?

ALVOGEN is the incumbent with $284.8M across 11 related awards in SCOUT’s public footprint. The current period of performance ends Jun 29, 2027.

When does 75A50325F80013 come up for recompete?

SCOUT tracks a period-of-performance end of Jun 29, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/V797D70134-75A50325F80013